CVCT

Welcome to the Global CardioVascular Clinical Trialists (CVCT) Forum. A meeting where our faculty members are selected from a list of world renowned global EXPERTS of the highest calibre. They are investigators and trial experts, industry R&D experts, regulatory and health technology experts, health care professional and health insurance experts, major media and medical journal experts and patient advocacy group experts to identify a few. It is this mix of expertise from various backgrounds which makes CVCT meetings unique, a sort of think tank, where faculty and participants alike are more willing to brainstorm and shift the lines than simply lecturing. CVCT meetings open up a number of engaging and interactive options, taking our participants on an expedition, making each session more productive and more effective. There is ample time in each session allowing for inspiring and energizing moderated multi-stakeholder expert panel debates (“The Forum”). Moderators interview the experts and engage participants to directly interview and challenge the experts, with the moderator streamlining this process. The moderators are encouraged to structure the discussion and split the timeslot into a few clear chapters. In addition to its classical features, CVCT Forum 2019 will be experimenting with another new variation to this theme are our Focused CVCT Workshops. Organized as campfire-sessions, fi t for smaller groups the expert and the participants sit in a small U shape-table, as equals. The experts are allowed very brief openings, but then it is over to the participants, with the hope that intimacy allows participants to feel freer to talk to the expert and to each other. Experts are encouraged to share their stories and case studies from real clinical trials, leaving it up to the audience to translate their learnings to their own daily reality, and to bring in more of their own cases. The real expertise is in the room and during breakouts, mingling and networking among the participants, which is why our CVCT Team encourages all experts to stay for the full forum. Don’t hold back in the discussions, it is through these discussions where the CVCT community learns from each other

Scroll down

cvct-2-35.jpg

CVCT is a true forum where scientific productivity and peer-to-peer exchange are at their best.

Knowledge-Sharing

The meeting encourages knowledge-sharing between participants as CVCT aims to familiarize practitioners and investigators with the science of clinical trials from protocol design to result interpretation. Further, CVCT Forum puts attendees into direct contact with primary investigators, senior trial scientists as well as research and development experts from pharmaceutical/device companies and experts from regulatory agencies.

cvct-2-621.jpg

A unique mix

Visuel-roue-CVCT_2019.png

The CVCT meetings are unique, bringing together a carefully selected faculty of Key Opinion Leaders (KOL), clinical trialists, investigators, regulators, statisticians, industry R&D experts, decision makers and practitioners. Over the years CVCT has attracted an audience from over 30 different countries, with participants coming from Western and Eastern Europe, the USA, Canada, South America, Asia and The Middle East.

This was truly one of the most interesting meetings I’ve ever attended, and I’ve blocked my calendar for next year.
— Ellis Unger, Acting Director, Office of New Drugs - Office of Dru g Evaluation I (ODE I), FDA, USA
 
It was a stimulating and interesting meeting.
— Robert Califf, Former Commissioner, Office of Medical Products and Tobacco, FDA, USA
 
Thank you for the amazing meeting and the great collaboration. This was an incredibly successful meeting with so much to
learn from!
— Roxana Mehran, Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials, Mount Sinai School of Medicine; Chief Scientific Officer, Clinical Trials Center, Cardiovascular Research Foundation, USA
 
It was really successful. I enjoyed particularly the discussions about differences between regulatory agencies, and regional differences in trials.
— Kaori Shinagawa, Senior Scientist for Clinical Medicine, Pharmaceuticals and Medical Devises Agency, Japan

cvct-2-1163.jpg
cvct-2-35.jpg